The tRF-3024b hijacks miR-192-5p to increase BCL-2-mediated resistance to cytotoxic T lymphocytes in Esophageal Squamous Cell Carcinoma
International Immunopharmacology · 2024-01 · 126 · 111135
DOI: 10.1016/j.intimp.2023.111135 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2024-01. Verfasst von Lin Wang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Department of Geriatric Lung Cancer Laboratory, The Affiliated Geriatric Hospital of Nanjing Medical University, Nanjing, Chi…. Hauptthemen laut MEDLINE: Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms, MicroRNAs. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Xuzhou Medical University, Natural Science Foundation of Jiangsu Province.
Abstract (Originalsprache)
The limited efficacy of immune checkpoint inhibitors (ICIs) in the treatment of advanced Esophageal Squamous Cell Carcinoma (ESCC) poses a challenge. Recent evidence suggests that tumor cells' insensitivity to cytotoxic T lymphocytes (CTLs) contributes to drug resistance against ICIs. Here, a particular tRNA-derived fragment called tRF-3024b has been identified as playing a significant role in tumor cell resistance to CTLs. Through tRF sequencing (tRF-seq), we observed a high expression of tRF-3024b in ESCC cells that survived co-culture with CTLs. Further in vitro studies demonstrated that tRF-3024b reduced the apoptosis of tumor cells when co-cultured with CTLs. The mechanism behind this resistance involves tRF-3024b promoting the expression of B-cell lymphoma-2 (BCL-2) by sequestering miR-192-5p, a microRNA that would normally inhibit BCL-2 expression. This means that tRF-3024b indirectly enhances the protective effects of BCL-2, reducing apoptosis in tumor cells. Rescue assays confirmed that the suppressive function of tRF-3024b relies on BCL-2. In summary, the tRF-3024b/miR-192-5p/BCL-2 axis sheds light on the crucial role of tRF-3024b in regulating BCL-2 expression. These findings offer valuable insights into strategies to enhance the response of ESCC to CTLs and improve the effectiveness of immunotherapy approaches in treating ESCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, Department of Geriatric Lung Cancer Laboratory, The Affiliated Geriatric Hospital of Nanjing Medical University, Nanjing, China.
- Department of Thoracic Surgery, Xuzhou Central Hospital, Xuzhou Clinical School of Xuzhou Medical University, Xuzhou, Jiangsu, China.
- Department of Cardiology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China.
- Department of Oncology, Xuzhou Central Hospital, Xuzhou Clinical School of Xuzhou Medical University, Xuzhou, Jiangsu, China. Electronic address: 361904345@qq.com.
- Department of Thoracic Surgery, Affiliated Cancer Hospital of Nanjing Medical University and Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research, Nanjing, China. Electronic address: maoqixing1@njmu.edu.cn.
- Department of Thoracic Surgery, Xuzhou Central Hospital, Xuzhou Clinical School of Xuzhou Medical University, Xuzhou, Jiangsu, China. Electronic address: surgeon_chen@yeah.net.
Förderung
- National Natural Science Foundation of China
- Xuzhou Medical University
- Natural Science Foundation of Jiangsu Province
- Hebei Provincial Health and Family Planning Commission
- Shanghai Xuhui District Central Hospital
- Xuzhou Municipal Science and Technology Bureau
Zitieren
APA
Wang, L., Peng, B., Yan, Y., Liu, G., Yang, D., Wang, Q., Li, Y., Mao, Q., & Chen, Q. (2024). The tRF-3024b hijacks miR-192-5p to increase BCL-2-mediated resistance to cytotoxic T lymphocytes in Esophageal Squamous Cell Carcinoma. International Immunopharmacology, 126, 111135. https://doi.org/10.1016/j.intimp.2023.111135
Vancouver
Wang L, Peng B, Yan Y, Liu G, Yang D, Wang Q, et al. The tRF-3024b hijacks miR-192-5p to increase BCL-2-mediated resistance to cytotoxic T lymphocytes in Esophageal Squamous Cell Carcinoma. International Immunopharmacology. 2024;126:111135. doi:10.1016/j.intimp.2023.111135
BibTeX
@article{Wang2024,
author = {Wang, Lin and Peng, Bo and Yan, Yan and Liu, Guangjun and Yang, Dunpeng and Wang, Qibin and Li, Yongcheng and Mao, Qixing and Chen, Qiang},
title = {The tRF-3024b hijacks miR-192-5p to increase BCL-2-mediated resistance to cytotoxic T lymphocytes in Esophageal Squamous Cell Carcinoma},
journal = {International Immunopharmacology},
year = {2024},
volume = {126},
pages = {111135},
doi = {10.1016/j.intimp.2023.111135}
}
EUVIMED